PerkinElmer CEO Cites Cell Screening Technologies as ‘Acquisition Priorities’
 
Recognizing the recent increased uptake of cell-based assays in drug discovery, a high-ranking PerkinElmer official last week said the company has made cellular screening technologies and related consumables and reagents “acquisition priorities,” and that it will continue to build out its cell-based screening platforms, particularly in the areas of GPCRs and kinases.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.